Complizen Learn

For most Class II medical devices cleared through the 510(k) pathway , companies should plan for multiple years from concept to commercial launch , not months. While every product is different, 18–36 months  is a common planning range once design complexity, testing, and regulatory realities are accounted for. FDA does not publish end-to-end “time-to-market” timelines. Delays usually come from underestimating development effort, testing lead times, and regulatory iteration ,

FDA expects performance testing that demonstrates your device functions as intended and does not raise different questions of safety or effectiveness compared to your predicate. The scope of testing depends on device type, risk, and technological differences, but most 510(k)s include bench or performance testing , software validation where applicable , and biocompatibility assessment for patient-contacting components . This guide shows you exactly which tests FDA requires for

If FDA disagrees with your predicate choice, you'll get an Additional Information (AI) request or a Not Substantially Equivalent (NSE) determination. AI requests often add months and require either: (1) switching to a different predicate, (2) providing stronger substantial equivalence rationale, or (3) withdrawing and refiling. Not Substantially Equivalent (NSE) determination usually means you must submit new 510(k) with different predicate or pursue De Novo. This guide walks

Human Factors Engineering (HFE), also called usability engineering, is how FDA expects you to show that intended users can operate your device safely and effectively in the intended use environment, especially when use error could cause harm. For many higher-risk device types, FDA often expects human factors data in 510(k)s and PMAs, and it is common to see it in De Novo programs when the user interface drives risk. If you change a user interface in a way that can affect comp

A new 510(k) is required if a modification could significantly affect the safety or effectiveness of the device  or represents a major change in intended use , per 21 CFR 807.81(a)(3) . FDA expects manufacturers to use its 2017 decision flowcharts  and a documented, risk-based assessment comparing the change to the most recently cleared device . Poor decisions can lead to costly enforcement, recalls, or unnecessary submissions. Every medical device company with a cleared 510(

A 510(k) submission costs between $50,000 and $250,000+ depending on device complexity, testing requirements, and whether you use consultants. Core costs include FDA user fees ($6,517-$26,067), testing/validation ($20,000-$150,000+), consultant fees ($15,000-$50,000), and establishment registration ($11,423). Most startups underestimate by 40-60%, with hidden costs from AI requests, design changes, and regulatory delays adding $30,000-$100,000+ to initial budgets. You've bui